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Background: While opportunistic infections and mortality
related to Human Immunodeﬁciency Virus (HIV) infection has
reduced signiﬁcantly following antiretroviral therapy (ART) scale-
up, non-AIDS events are emerging causes of death. This study
determined the prevalence and incidence of dysglycaemia in adult
South African black subjects of second generation Zulu descent.
Methods & Materials: The study included HIV infected ART
naive patientswhowere eligible for ART (group 1, n =150), and age,
gender, and ethnicallymatchedHIV infected subjectswhowerenot
eligible for ART (group 2, n =88) and HIV negative subjects (group
3, n =88). WHO criteria for disorders of glycaemia were used to
compare the three groups for the prevalence of diabetes melli-
tus (DM), impaired glucose tolerance (IGT) and impaired fasting
glucose (IFG), using the oral glucose tolerance test and HBA1c at
baseline (Yr0)prior togroup1commencingART (tenofovir, lamivu-
dine, efavirenz/nevirapine). Group 1was followed for 24months or
longer on ART to determine the incidence of dysglycaemia. Poisson
approximations were used to estimate incidence.
Results: At baseline, the prevalence of DMwas 0% in group 1and
2, 4.94% in group3 (p=0.005).The prevalence of IGTwas 2.96%, 2.4%
and 3.7% and of IFG, 0.7%. 1.2% and 0% in group 1, 2 and 3, respec-
tively. Multivariate analysis showed that systolic blood pressure
(OR 1.3 [95% CI 1.1-1.6] p =0.002) and triglycerides (OR 4.1[95%
CI 1.0-16.6] p =0.05) were signiﬁcant risk factors for DM. In the
follow-up study, of 150 HIV infected persons on ART, 13 developed
DM during 219.2 person-years follow up (PYFU), with an incidence
of 5.9 cases per 100 PYFU (95% CI 3.2 – 10.1); 11 developed IGT
during 217.9 PYFU (incidence: 5.0 cases per 100 PYFU [95% CI 2.5
to 9]) and 8 developed IFG during 216.3 PYFU (incidence: 3.7 cases
per 100 PYFU [95% CI 1.6 – 7.3]). In multivariate analysis, systolic
blood pressure was a signiﬁcant predictor of IGT and IFG
Conclusion: The incidence of DM in HIV infected patients on
ART is high. Patient monitoring in developing countries must also
focus on metabolic complications of ART.
http://dx.doi.org/10.1016/j.ijid.2014.03.425
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While non-typhoidal Salmonella (NTS) have long been known
to be a cause of self-limited gastroenteritis, it is becoming increas-
ingly recognized that multiple antibiotic-resistant strains are also
emerging as important causes of invasive bacteremia and focal
infections, resulting in hospitalizations and deaths. Surveys from
multiple sites in sub-Saharan Africa reveal that ∼ 75-90% of NTS
from cases of invasive disease are Salmonella Typhimurium (and
the monophasic S. Typhimurium variant S. I 4,[5],12:i:-), serovars
that fall into Salmonella group B, or Salmonella Enteritidis, a groupD
Salmonella serovar. An effective NTS vaccine directed against these
serovars could thus provide broad protection.Wehave constructed
attenuated S. Typhimurium and S. Enteritidis strains that can serve
as live oral vaccines as well as “reagent strains” for improved pro-
duction of conjugate vaccine components. Live oral vaccine strains
CVD 1931 (S. Typhimurium D65 guaBA clpX) and CVD 1944 (S.
Enteritidis R11 guaBA clpX)were shown to protectmice against
a high challenge dose (10,000 X LD50) with invasive African clini-
cal isolates. Cross-protection experiments revealed that these live
NTS vaccines also protect mice against other invasive Group B and
D serovars. In parallel, we have developed S. Enteritidis conjugate
vaccines using S. Enteritidis ﬂagellin FliC as a carrier protein, chem-
ically linked to homologous lipopolysaccharide-derived Core and
O-polysaccharide (COPS), puriﬁed from S. Enteritidis R11 guaBA
clpPX expressing ﬂagellin at high levels. Various candidate con-
jugates were constructed by linkage to solvent-exposed lysines on
FliC either at random COPS hydroxyls with CDAP chemistry, or at
the Core-KDO terminuswith thioether chemistry.Mice immunized
with COPS:FliC conjugates were signiﬁcantly protected from lethal
challenge with an invasive African S. Enteritidis clinical isolate,
demonstrating 80-100% vaccine efﬁcacy. Protection was further
maintained in mice immunized with fractional COPS:FliC doses
thatdidnot stimulatehighCOPS-speciﬁcantibody levels, indicating
the potency of our conjugate vaccines. Since S. Typhimurium and
S. Enteritidis are the most common NTS serovars associated with
invasive disease, this research can pave the way for development
of highly effective, broad spectrum vaccines against NTS.
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